2. Search Result
Search Result
Results for "

peptide ligand

" in MedChemExpress (MCE) Product Catalog:

167

Inhibitors & Agonists

1

Fluorescent Dyes

20

Biochemical Assay Reagents

140

Peptides

2

MCE Kits

3

Inhibitory Antibodies

3

Natural
Products

1

Antibodies

5

Click Chemistry

14

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0224
    N-Formyl-Met-Leu-Phe
    Maximum Cited Publications
    16 Publications Verification

    fMLP; N-Formyl-MLF

    		 TNF Receptor Inflammation/Immunology
    N-Formyl-Met-Leu-Phe (fMLP; N-Formyl-MLF) is a chemotactic peptide and a specific ligand of N-formyl peptide receptor (FPR). N-Formyl-Met-Leu-Ph is reported to inhibit TNF-alpha secretion.
    N-Formyl-Met-Leu-Phe
  • HY-P1740
    RGD peptide (GRGDNP)
    5+ Cited Publications

    		 Integrin Apoptosis Caspase Inflammation/Immunology
    RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation .
    RGD peptide (GRGDNP)
  • HY-43869
    Vipivotide tetraxetan Ligand-Linker Conjugate

    PSMA-617 ligand-Linker Conjugate

    		 ADC Linker Cancer
    Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is a complex composed of pharmacophore group Glutamate-urea-Lysine peptide coupling linker, which can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine selectively binds to prostate-specific membrane antigen (PSMA) .
    Vipivotide tetraxetan Ligand-Linker Conjugate
  • HY-P3108
    Alamandine
    2 Publications Verification

    		 Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Alamandine, a member of the renin-angiotensin system (RAS), a vasoactive peptide, is an endogenous ligand of the G protein-coupled receptor MrgD. Alamandine targets to protect the kidney and heart through anti-hypertensive actions .
    Alamandine
  • HY-P10945
    FAP targeting peptide for FXX489

    		Radionuclide-Drug Conjugates (RDCs) FAP Cancer
    FAP targeting peptide for FXX489 is the polypeptide part of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand .
    FAP targeting peptide for FXX489
  • HY-P10709
    CREKA peptide

    		Collagen Cardiovascular Disease Cancer
    CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects .
    CREKA peptide
  • HY-P99017
    Eptinezumab

    ALD-403

    		 CGRP Receptor Neurological Disease
    Eptinezumab (ALD-403) is a human monoclonal antibody targeting the α and β subtypes of human calcitonin gene-related peptide (CGRP). Eptinezumab binds to the CGRP ligand and blocks its binding to endogenous CGRP receptors, thereby inhibiting receptor activation. Eptinezumab can be used in research related to migraine .
    Eptinezumab
  • HY-P2268
    RAGE antagonist peptide
    4 Publications Verification

    		 Amyloid-β Inflammation/Immunology Cancer
    RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide (RAP) possesses anti-tumor and anti-inflammatory activities .
    RAGE antagonist peptide
  • HY-P11328
    GFOGER peptide

    		Integrin Others
    GFOGER peptide is an artificially synthesized collagen-mimetic sequence. GFOGER peptide acts as a ligand for α2β1, α11β1 and α1β1 integrins, thereby supporting integrin-mediated cell adhesion to collagen. GFOGER peptide triggers signaling pathways mediated by the α2β1 integrin receptor and upregulates osteoblast differentiation. GFOGER peptide accelerates and enhances bone formation at sites of refractory femoral defects. GFOGER peptide can be passively adsorbed onto polymer scaffolds for cell-free/growth factor-free bone formation. GFOGER peptide is used in biomaterials such as hydrogels and 3D bioinks for tissue engineering research including bone formation .
    GFOGER peptide
  • HY-P11099
    Cys-LT7

    		Transferrin Receptor Neurological Disease Cancer
    Cys-LT7 is a transferrin receptor (TfR)-targeting peptide ligand. Cys-LT7 binds to a TfR site distinct from endogenous transferrin, mediates conjugated Doxorubicin (HY-15142A) delivery to TfR-overexpressed tumor cells, and exhibits low toxicity to TfR-low-expressed normal cells. Cys-LT7 is an L-configuration peptide susceptible to proteolytic enzymes, leading to poor biostability in peptide-drug conjugates. Cys-LT7 can be used for the research of glioblastoma, hepatocellular carcinoma, lung carcinoma .
    Cys-LT7
  • HY-P3732
    RGD-4C

    		Integrin Cancer
    RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .
    RGD-4C
  • HY-P1868
    α2β1 Integrin Ligand Peptide
    3 Publications Verification

    DGEA peptide

    		 Integrin Infection
    α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .
    α2β1 Integrin Ligand Peptide
  • HY-P0272
    Peptide T

    		HIV Infection
    Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.
    Peptide T
  • HY-164166
    Fmoc-Sar-Sar-Sar-OH

    		Biochemical Assay Reagents Drug Intermediate Amino Acid Derivatives Others
    Fmoc-Sar-Sar-Sar-OH is a small molecule polypeptide composed of sarcosine residues, in which the N-terminus of the peptide chain is protected by Fmoc. Fmoc-Sar-Sar-Sar-OH can be used for peptide synthesis or synthesis of agent-peptide ligand conjugates .
    Fmoc-Sar-Sar-Sar-OH
  • HY-P2268A
    RAGE antagonist peptide TFA
    4 Publications Verification

    		 Amyloid-β Inflammation/Immunology Cancer
    RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities .
    RAGE antagonist peptide TFA
  • HY-P1740A
    RGD peptide (GRGDNP) TFA
    5+ Cited Publications

    		 Integrin Apoptosis Inflammation/Immunology Cancer
    RGD peptide (GRGDNP) TFA is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) TFA competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) TFA promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) TFA plays an important role in cell adhesion, migration, growth, and differentiation .
    RGD peptide (GRGDNP) TFA
  • HY-P11228
    FPP29

    		PROTACs Apoptosis DNA/RNA Synthesis Cancer
    FPP29 is a potent peptide-based FOXM1 PROTAC degrader. FPP29 induces ubiquitination and degradation of FOXM1. FPP29 inhibits FOXM1 via the ubiquitin-proteasome degradation pathway. FPP29 induces Apoptosis. FPP29 suppresses tumor growth in hepatocellular carcinoma xenograft models. FPP29 can be used in the research of hepatocellular carcinoma (cell-penetrating peptide: (HY-P0133); VHL ligase ligand: (HY-P11493); linker: (HY-W013664); FOXM1 ligand: (HY-P11494)) .
    FPP29
  • HY-P3440
    WL12

    		Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1 Cancer
    WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .
    WL12
  • HY-P3436
    WLSEAGPVVTVRALRGTGSW

    		Exosomes Cardiovascular Disease
    WLSEAGPVVTVRALRGTGSW is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure) .
    WLSEAGPVVTVRALRGTGSW
  • HY-155788
    DSPE-PEG-DBCO ammonium

    		Biochemical Assay Reagents Others
    DSPE-PEG-DBCO ammonium is the ammonium salt form of DSPE-PEG-DBCO. DSPE-PEG-DBCO ammonium is utilized in copper-free click chemistry through SPAAC conjugation with an azido-functionalized peptide ligand. DSPE-PEG-DBCO ammonium is applied in drug-delivery and nanoparticle research .
    DSPE-PEG-DBCO ammonium
  • HY-P5832
    BMP2-derived peptide

    		TGF-beta/Smad RUNX Metabolic Disease
    BMP2-derived peptide is an osteogenic inducer and BMP receptor ligand. BMP2-derived peptide binds to BMP receptors on the cell surface to form a complex, activates the downstream Smad signaling pathway, and regulates the expression of osteogenic transcription factors. BMP2-derived peptide effectively promotes the adhesion, proliferation, osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells, significantly up-regulates the mRNA levels of OCN, Runx2 and type I collagen, and increases alkaline phosphatase activity and calcium deposition. BMP2-derived peptide induces osteoblast differentiation and ectopic bone regeneration, and improves cranial bone defect repair. Meanwhile, BMP2-derived peptide enhances the cytocompatibility of mesoporous silica nanoparticles, synergistically increases osteogenic activity with Dexamethasone (HY-14648), serving as an important tool for bone defect repair research .
    BMP2-derived peptide
  • HY-P1868A
    α2β1 Integrin Ligand Peptide TFA
    3 Publications Verification

    DGEA peptide TFA

    		 Integrin Others
    α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .
    α2β1 Integrin Ligand Peptide TFA
  • HY-P4803
    PAR-2 (1-6) (human)
    2 Publications Verification

    		 Protease Activated Receptor (PAR) Inflammation/Immunology
    PAR-2 (1-6) (human) (SLIGKV), a peptide ligand, is a PAR-2 agonist .
    PAR-2 (1-6) (human)
  • HY-P10950A
    PD-L1 inhibitory peptide TFA

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-L1 inhibitory peptide TFA is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide TFA binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide TFA is promising for research of cancers .
    PD-L1 inhibitory peptide TFA
  • HY-P2264
    KYL peptide
    3 Publications Verification

    		 Ephrin Receptor Inflammation/Immunology
    KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor (IC50:4.22 μM, Kd:1.3 μM). KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses .
    KYL peptide
  • HY-P1039A
    R18 TFA

    PHCVPRDLSWLDLEANMCLP TFA

    		 Raf Cancer
    R18 TFA is a peptide antagonists of 14-3-3, with a KD of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .
    R18 TFA
  • HY-P5464
    SRC-1 NR box peptide

    		Estrogen Receptor/ERR Others
    SRC-1 NR box peptide is a biological active peptide (This peptide is a 14-amino acid fragment from the steroid receptor cofactor SRC-1 NR II). SRC-1 NR box peptide can be used to study the regulatory mechanisms of estrogen receptor ligands .
    SRC-1 NR box peptide
  • HY-P10501A
    FRα-targeting peptide C7 TFA

    		Antifolate Cancer
    FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment .
    FRα-targeting peptide C7 TFA
  • HY-P1186
    Eledoisin Related Peptide

    Eledoisin-Related peptide; Eledoisin RP

    		 Neurokinin Receptor Neurological Disease
    Eledoisin Related Peptide is a Substance P analog that excites neurons and triggers behavioral responses. Eledoisin Related Peptide is also a tachykinin receptor ligand.
    Eledoisin Related Peptide
  • HY-P1520
    Prolactin Releasing Peptide (1-31), human

    		GnRH Receptor Neurological Disease
    Prolactin Releasing Peptide (1-31), human is a high affinity GPR10 ligand that cause the release of the prolactin. Prolactin Releasing Peptide (1-31) binds to GPR10 for human and rats with Ki values of 1.03 nM and 0.33 nM, respectively. Prolactin Releasing Peptide (1-31) can be used for the research of the hypothalamo-pituitary axis .
    Prolactin Releasing Peptide (1-31), human
  • HY-P1520A
    Prolactin Releasing Peptide (1-31), human acetate

    		GnRH Receptor Neurological Disease
    Prolactin Releasing Peptide (1-31), human (acetate) is a high affinity GPR10 ligand that causes the release of the prolactin. Prolactin Releasing Peptide (1-31) binds to GPR10 for human and rats with Ki values of 1.03 nM and 0.33 nM, respectively. Prolactin Releasing Peptide (1-31) can be used for the research of the hypothalamo-pituitary axis .
    Prolactin Releasing Peptide (1-31), human acetate
  • HY-P11050A
    SP94

    		Apoptosis Cancer
    SP94 is a peptide ligand with high specificity for hepatocellular carcinoma cells. SP94 selectively binds to multiple hepatocellular carcinoma cell lines in vitro. SP94 inhibits tumor growth in a mouse model of hepatocellular carcinoma by promoting apoptosis and reducing angiogenesis. SP94 can be used as a specific probe for hepatocellular carcinoma imaging. SP94 is useful for hepatocellular carcinoma research .
    SP94
  • HY-W343750
    [Tyr4]-Bombesin

    		Bombesin Receptor Metabolic Disease
    [Tyr4]-Bombesin is a Bombesin analogue, is a ligand of gastrin-releasing peptide receptor (GRPR) .
    [Tyr4]-Bombesin
  • HY-P10950
    PD-L1 inhibitory peptide

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers .
    PD-L1 inhibitory peptide
  • HY-P1507
    Fibrinogen Binding Inhibitor Peptide

    		Integrin Cardiovascular Disease
    Fibrinogen Binding Inhibitor Peptide is a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). Fibrinogen Binding Inhibitor Peptide is a specific binding site of the ligand for activated glycoprotein (GP) IIb/IIIa.
    Fibrinogen Binding Inhibitor Peptide
  • HY-W717830
    CB-Cyclam

    		Biochemical Assay Reagents Others
    CB-Cyclamis a bifunctional chelator (Bifunctional Chelator; BFC), which is a main chain Cyclen derivative of the macrocyclic ligand tetradecane. CB-Cyclam can be used for conjugation of peptides and radionuclides.
    CB-Cyclam
  • HY-P10529
    Ganglioside GM1-binding peptide p3

    		Trk Receptor Infection
    Ganglioside GM1-binding peptide p3 is a synthetic peptide that can specifically bind to the pentasaccharide part of GM1 ganglioside. The dynamic transformation of Ganglioside GM1-binding peptide p3 may play an important role in the function of GM1 as a multiple receptor, such as in the classical pathway of cholera toxin infection. Ganglioside GM1-binding peptide p3 can be used to study the interaction between GM1 and its ligands .
    Ganglioside GM1-binding peptide p3
  • HY-172273A
    DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY

    		Liposome Cancer
    DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep, YEQDPWGVKWWY). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY can be used for drug delivery .
    DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY
  • HY-168535
    SJ6145

    		Ligands for E3 Ligase Cancer
    SJ6145 is a potent ligand for KLHDC2 SBD, with the Kd of 16.9 μM in SPR test, IC50 value of 42 μM in inhibiting KLHDC2 SBD binding to a di-Gly degron peptide test .
    SJ6145
  • HY-P5964A
    K1 peptide TFA

    		GABA Receptor Neurological Disease
    K1 peptide TFA is a high-affinity peptide ligand for GABAA receptor-associated protein (GABARAP) .
    K1 peptide TFA
  • HY-P5464A
    SRC-1 NR box peptide acetate

    		Estrogen Receptor/ERR Endocrinology
    SRC-1 NR box peptide acetate is a biological active peptide (This peptide is a 14-amino acid fragment from the steroid receptor cofactor SRC-1 NR II). SRC-1 NR box peptide acetate can be used to study the regulatory mechanisms of estrogen receptor ligands .
    SRC-1 NR box peptide acetate
  • HY-P4015
    VIP (1-12), human, porcine, rat, ovine

    		HIV Neurological Disease Metabolic Disease
    VIP (1-12), human, porcine, rat, ovine is a vasoactive intestinal peptide (VIP) fragment. VIP (1-12), human, porcine, rat, ovine is a ligand for the CD4 (T4)/human immunodeficiency virus receptor .
    VIP (1-12), human, porcine, rat, ovine
  • HY-P3130
    Stresscopin-related peptide (human)

    		CRFR Neurological Disease Inflammation/Immunology
    Stresscopin-related peptide (human) is a specific ligand for the type 2 CRH receptor. Stresscopin-related peptide (human) suppresses food intake, delayed gastric emptying and decreases heat-induced edema. Stresscopin-related peptide (human) maintains homeostasis after stress, and can be used in the research of stress-related diseases .
    Stresscopin-related peptide (human)
  • HY-P10997
    F3 peptide

    		DNA/RNA Synthesis Cancer
    F3 peptide is a fragment of the human high mobility group protein 2 (HMGB2), and can specifically bind to nucleolin expressed on the membrane of cancer cells, neovasculature, and endothelium. F3 peptide can be used as an effective ligand to improve their druggability of macromolecular drugs or nanoparticles, and so on .
    F3 peptide
  • HY-P11286
    A7RC

    		Complement System Cancer
    A7RC is a multifunctional peptide used in tumor-targeted therapy, with Cysteine added to the C-terminal of the A7R peptide (sequence: ATWLPPR). A7R (HY-P1663) is a ligand of the NRP-1 receptor, regulating intracellular signal transduction related to tumor vascularization and tumor growth .
    A7RC
  • HY-172273
    DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY

    		Liposome Cancer
    DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep, YEQDPWGVKWWY). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY can be used for drug delivery .
    DSPE-PEG1000-Mal-Cys-YEQDPWGVKWWY
  • HY-P10495
    GPR110 peptide agonist P12

    		Transmembrane Glycoprotein Others Cancer
    GPR110 peptide agonist P12 is a peptide that acts as a GPR110 agonist. GPR110 peptide agonist P12 can significantly enhance the initial rate of GPR110 stimulated G protein GTPγS binding. GPR110 peptide agonist P12 mimics the action of natural ligands, causing the extracellular domain (ECD) of the GPR110 to dissociate from the seven transmembrane domains (7TM), exposing the β-strand-13/stalk region at the N-terminus of the 7TM domain, which acts as an agonist to activate G protein signaling. GPR110 peptide agonist P12 can be used in the study of developmental disorders and cancers related to GPR110 .
    GPR110 peptide agonist P12
  • HY-P5325A
    Bid BH3 (80-99) acetate

    		Bcl-2 Family Others
    Bid BH3 (80-99) acetate is a biological active peptide. (BID is a pro-apoptotic member of the 'BH3-only' (BOPS) subset of the BCL-2 family of proteins that constitute a critical control point in apoptosis. Bid is the first of the BOPs reported to bind and activate Bcl-2, Bax, and Bak. Bid serves as a death-inducing ligand that moves from the cytosol to the mitochondrial membrane to inactivate Bcl-2 or to activate Bax.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)
    Bid BH3 (80-99) acetate
  • HY-P5325
    Bid BH3 (80-99)

    		Bcl-2 Family Others
    Bid BH3 (80-99) is a biological active peptide. (BID is a pro-apoptotic member of the 'BH3-only' (BOPS) subset of the BCL-2 family of proteins that constitute a critical control point in apoptosis. Bid is the first of the BOPs reported to bind and activate Bcl-2, Bax, and Bak. Bid serves as a death-inducing ligand that moves from the cytosol to the mitochondrial membrane to inactivate Bcl-2 or to activate Bax.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)
    Bid BH3 (80-99)
  • HY-P1039
    R18

    PHCVPRDLSWLDLEANMCLP

    		 Raf Cancer
    R18 is a peptide antagonists of 14-3-3, with a KD of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .
    R18

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: